Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

This is a first-in-human Phase 1, multi-center, open-label, dose-escalation study to: * Evaluate the safety profile of RP-3467 when administered orally alone and in combination with olaparib and to define the MTD or MAD for RP-3467 monotherapy and the RP2D for the combination * Characterize the PK profile of RP-3467 alone and in combination with olaparib